Amendment to Amended and Restated Agreement Between Genentech, Inc. and F. Hoffmann-La Roche Ltd Regarding Commercialization of Genentech's Products Outside the United States

EXHIBIT 10.18

Amendment to Amended and Restated Agreement Between Genentech, Inc.
and X. Xxxxxxxx-Xx Xxxxx Ltd Regarding Commercialization of Genentech's
Products Outside the United States

            This Amendment to Amended and Restated Agreement Between Genentech, Inc. and X. Xxxxxxxx-Xx Xxxxx Ltd Regarding Commercialization of Genentech's Products Outside the United States (hereinafter, "Amendment") is made, effective as of March 10, 2000 ("Amendment Effective Date"), by and among X. Xxxxxxxx-Xx Xxxxx Ltd, Xxxxxxxxxxxxxxxxx 000, XX 4070 Basel, Switzerland ("ROCHE"), Genentech, Inc., 0 XXX Xxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx XXX 00000, Genentech Europe Limited, Xxxx House, 31 Church Street, Xxxxxxxx, Bermuda HM FXV and Genentech Biopharmaceuticals Limited, Xxxx House, 31 Church Street, Xxxxxxxx, Bermuda HM FXV ("GENENTECH").

WHEREAS, ROCHE and GENENTECH have entered into that certain Amended and Restated Agreement Between Genentech, Inc. and X. Xxxxxxxx-Xx Xxxxx Ltd Regarding Commercialization of Genentech's Products Outside the United States (hereinafter, the "Commercialization Agreement").

WHEREAS, ROCHE now wishes to not commercialize and market in Canada GENENTECH's interferon gamma, Actimmune and to amend the Commercialization Agreement with respect to this.

NOW, THEREFORE, THE PARTIES HERETO HEREBY AGREE AS FOLLOWS:

1. All capitalized terms in this Amendment shall have the meanings given in the Commercialization Agreement unless otherwise expressly defined herein.
    
2. Article 1, Section 5 of the Commercialization Agreement is hereby amended to delete Actimmune interferon gamma from the definition of "Canada Products."
    
3. Except as expressly amended herein above, all of the terms and conditions of the Commercialization Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representative as of the Amendment Effective Date.

GENENTECH, INC.			XXXXXXXX-XX XXXXX LTD
By:	/s/ XXXXXXX X. XXXXXXXXXX		By:	/s/ XXXXXX XXXXXX
Name:	Xxxxxxx X. Xxxxxxxxxx		Name:	Xxxxxx Xxxxxx
Title:	Senior Vice President and General Counsel		Title:	Vice Director
			By:	/s/ X. XXXXXXXXX
			Name:	X. Xxxxxxxxx
			Title:	MP Director
GENENTECH EUROPE LIMITED
By:	/s/ XXXXX X. XXXXXXX, XX.
Name:	Xxxxx X. Xxxxxxx, Xx.
Title:	Vice President and Chief Financial Officer
GENENTECH BIOPHARMACEUTICALS LIMITED
By:	/s/ XXXXX X. XXXXXXX, XX.
Name:	Xxxxx X. Xxxxxxx, Xx.
Title:	Vice President and Chief Financial Officer